Quantum Genomics (France) Executives
| ALQGC Stock | EUR 0.07 0 1.77% |
Quantum Genomics employs about 8 people. The company is managed by 5 executives with a total tenure of roughly 5 years, averaging almost 1.0 years of service per executive, having 1.6 employees per reported executive. Discussion of Quantum Genomics' management performance can provide insight into the enterprise performance.
| JeanPhilippe Milon President Vice President - Operations |
Quantum |
Quantum Genomics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4751) % which means that it has lost $0.4751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2274) %, meaning that it generated substantial loss on money invested by shareholders. Quantum Genomics' management efficiency ratios could be used to measure how well Quantum Genomics manages its routine affairs as well as how well it operates its assets and liabilities.Quantum Genomics Workforce Comparison
Quantum Genomics SA is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 296. Quantum Genomics holds roughly 8.0 in number of employees claiming about 2.7% of equities under Health Care industry.
Quantum Genomics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Quantum Genomics Price Series Summation is a cross summation of Quantum Genomics price series and its benchmark/peer.
Quantum Genomics Notable Stakeholders
A Quantum Genomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Quantum Genomics often face trade-offs trying to please all of them. Quantum Genomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Quantum Genomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JeanPhilippe Milon | Vice President - Operations | Profile | |
| Stephane Cohen | Chief Officer | Profile | |
| Sarah MerlenBoulenger | Head Affairs | Profile | |
| Bruno Besse | Chief Officer | Profile | |
| Benot Gueugnon | VP Director | Profile |
About Quantum Genomics Management Performance
The success or failure of an entity such as Quantum Genomics often depends on how effective the management is. Quantum Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Quantum management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Quantum management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.
Quantum Genomics Workforce Analysis
Traditionally, organizations such as Quantum Genomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Quantum Genomics within its industry.Quantum Genomics Manpower Efficiency
Return on Quantum Genomics Manpower
| Revenue Per Employee | 14.5K | |
| Revenue Per Executive | 23.2K | |
| Net Loss Per Employee | 2.2M | |
| Net Loss Per Executive | 3.5M |
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.